Literature DB >> 28400267

CHD5 is a potential tumor suppressor in non small cell lung cancer (NSCLC).

Onur Baykara1, Merve Tansarikaya1, Pelin Bulut1, Ahmet Demirkaya2, Nur Buyru3.   

Abstract

Lung cancer is one of the deadliest types of cancers and genetic and epigenetic alterations play major roles in its development. Chromodomain (CHD) protein family acts in chromatin organization, regulation of transcription and also genomic stability and cancer prevention. Although CHD5, a member of this family was shown to contribute to major cellular events and functions as a tumor suppressor gene in various types of cancer, it is not clear whether CHD5 plays a role in lung carcinogenesis. The aim of this study was to investigate the possible role of CHD5 in progression of non-small cell lung cancer (NSCLC). Expression levels of CHD5 gene in 59 tumor and corresponding non-cancerous lung tissue samples were analyzed by qRT-PCR and the methylation status of the promoter region was investigated by methylation specific PCR (MS-PCR). The Akt phosphorylation levels were investigated by Western Blot (WB). CHD5 was down-regulated in 17 (39.5%) and up-regulated in 24 (55.8%) of tumor specimens. Even though the promoter of CHD5 was hypermethylated in 8 patients, it was not found associated with CHD5 gene expression (p=0.08). Akt phosphorylation was increased in 14 (53.8%) and decreased in 12 (46.2%) of the samples but no significant association was found between p-Akt phosphorylation and CHD5 expression (p=0.67). We suggest that CHD5 may act as a tumor suppressor gene in NSCLC.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CHD5; Chromodomain; Lung cancer; NSCLC

Mesh:

Substances:

Year:  2017        PMID: 28400267     DOI: 10.1016/j.gene.2017.04.010

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  7 in total

1.  Clinical significance of chromatin remodeling factor CHD5 expression in gastric cancer.

Authors:  Tadayoshi Hashimoto; Yukinori Kurokawa; Noriko Wada; Tsuyoshi Takahashi; Yasuhiro Miyazaki; Koji Tanaka; Tomoki Makino; Makoto Yamasaki; Kiyokazu Nakajima; Masaki Mori; Yuichiro Doki
Journal:  Oncol Lett       Date:  2019-11-21       Impact factor: 2.967

2.  Transcriptome profiling reveals PDZ binding kinase as a novel biomarker in peritumoral brain zone of glioblastoma.

Authors:  Banavathy S Kruthika; Ruchi Jain; A Arivazhagan; R D Bharath; T C Yasha; Paturu Kondaiah; Vani Santosh
Journal:  J Neurooncol       Date:  2018-11-20       Impact factor: 4.130

3.  Chromodomain Helicase DNA-Binding Protein 5 Inhibits Renal Cell Carcinoma Tumorigenesis by Activation of the p53 and RB Pathways.

Authors:  Sheng Huang; Qitao Yan; Shilin Xiong; Yiqi Peng; Rui Zhao; Chunxiao Liu
Journal:  Biomed Res Int       Date:  2020-09-28       Impact factor: 3.411

4.  Pan-Cancer Analysis Identifies CHD5 as a Potential Biomarker for Glioma.

Authors:  Lei Xu; Fengling Shao; Tengling Luo; Qijun Li; Dongmei Tan; Yi Tan
Journal:  Int J Mol Sci       Date:  2022-07-30       Impact factor: 6.208

5.  A rare CHD5 haplotype and its interactions with environmental factors predicting hepatocellular carcinoma risk.

Authors:  Qin Xiao; Lianzhou Chen; Haiqing Luo; Hongmei Li; Qingming Kong; Fei Jiao; Shifeng Pang; Ming Zhang; Feifei Lan; Wenguo Fan; Hui Luo; Tao Tao; Xiao Zhu
Journal:  BMC Cancer       Date:  2018-06-15       Impact factor: 4.430

6.  MiR‑500a‑5p promotes glioblastoma cell proliferation, migration and invasion by targeting chromodomain helicase DNA binding protein 5.

Authors:  Zhiyong Liu; Danying Su; Xiuying Qi; Jing Ma
Journal:  Mol Med Rep       Date:  2018-07-09       Impact factor: 2.952

7.  Overexpression of chromodomain helicase DNA binding protein 5 (CHD5) inhibits cell proliferation and induces cell cycle arrest and apoptosis in chronic myeloid leukemia.

Authors:  Shilin Xiong; Qitao Yan; Yiqi Peng; Sheng Huang; Rui Zhao
Journal:  Transl Cancer Res       Date:  2021-02       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.